The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas
about
Treatment of Cushing disease: overview and recent findingsTreatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.Pituitary somatostatin receptor signalingThe Treatment of Cushing's Disease.Cushing's disease: a multidisciplinary overview of the clinical features, diagnosis, and treatmentTemozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expressionProlactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.Clinical Guidelines for the Diagnosis and Treatment of Cushing's Disease in Korea.Treatment Options in Cushing's Disease.Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion.Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumorsTreatment of Cushing's Syndrome: An Endocrine Society Clinical Practice GuidelineMedical management of functioning pituitary adenoma: an update.Medical management of Cushing's disease: what is the future?Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine cushing's diseasePharmacoeconomic aspects of the treatment of pituitary gland tumours.Endocrine clinical update: where are we in the therapeutic management of pituitary-dependent hypercortisolism?A survey of clinical practice patterns in diagnosis and management of Cushing's disease in Iran.New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapyFuture treatment strategies of aggressive pituitary tumors.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology.The somatostatin receptor subtype 5 in neuroendocrine tumours.Pasireotide for the treatment of Cushing's disease.Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implicationsPituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review.Mifepristone: is there a place in the treatment of Cushing's disease?Pasireotide: a review of its use in Cushing's disease.Recent developments in drug therapy for Cushing's disease.Molecular basis of pharmacological therapy in Cushing's disease.Pituitary-directed medical therapy in Cushing's disease.Emerging drugs for Cushing's disease.USP8: a novel therapeutic target for Cushing's disease.Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing's disease.Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation.Antiproliferative effects of somatostatin analogs in endocrine tumours.Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitroThe role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study.New treatment guidelines on Cushing's disease.Effectiveness of low-dose pasireotide in a patient with Cushing's disease: antiproliferative effect and predictivity of a short pasireotide suppression test.Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease.
P2860
Q24626819-DEAE664D-8116-433A-A284-C7AFF6BDAAFEQ24629410-7ACD050A-2132-4B54-AC78-63184622EAA0Q24631604-15848406-5E17-4BC2-A59C-8A6F2F501E17Q27010590-03B8007D-1AF5-4764-9A8D-D7335A9E9616Q28071635-A7BAF91F-10FE-445C-A9A2-B8593DB488F1Q30353110-0ED6AC38-C0E4-4763-825A-4B6E0DE3DFA3Q33579615-3E3DBAD8-8386-4ACA-8B6E-CEF86A8AE3A1Q35260959-77F837A9-7255-4D62-A949-BA3C5B49988CQ35740882-269119C5-3B69-454F-A62D-2C7BF1BE34FBQ35744515-025330FB-204C-4873-9296-93EAA1602567Q35747137-A154C8E1-006E-4B49-A995-B1D551176438Q35916555-BE567F3A-BC6E-46C2-B6F8-82D530CFE5D0Q35943493-55D098ED-8B5D-4398-9065-5F269BC4F836Q36236884-4EFD1070-04CF-4EC9-8259-229CD542D298Q36908926-FAE7A993-D1C8-405F-BB43-EFB227524F53Q36936833-CADE27D2-AA1D-4004-A1C6-018C23F50291Q36940053-3D413EC6-3F7A-46F9-890E-2F5FE9F36400Q36983219-4F1B92C9-AE68-49C2-8CD2-98C93DCACA03Q37049132-F187FCE5-E083-41D0-A13B-5DB5F4DF3427Q37266737-5FA552C7-3DAF-4928-BE19-4BDCA8A62EDBQ37579225-DE51C89D-23F2-4CF1-9065-0696F2782159Q37691450-6746D94A-0BD7-455E-B9A7-FF0632A2A98CQ37763714-A2E3549E-F5B7-4A4A-B1E0-657C478337D5Q37772579-E49D2486-82DB-4006-9D95-817F31430EBEQ38037355-1B4C4214-1F76-4D68-AD90-F2656839491FQ38063404-4F35FA9F-929E-4332-BCBA-85BE0FBE1164Q38100715-82045118-26C2-4469-A2B3-5DBCF371DC5EQ38112082-939F340C-EAE7-47C0-8F5E-741277D405E1Q38165863-2C163823-FB99-4BF5-8E97-DD82F88A863DQ38334659-33277516-69C5-4C40-85B1-D17AFA476493Q38505947-D7155AE9-B8D1-48CD-B929-9A73DA38CA67Q38545050-1CCD9C62-2C1A-4F3F-B676-8AF7C353FB15Q39551743-3B6B5D99-6F71-4AC3-90BB-49D8BAADC997Q39741277-5A14B3EB-75DF-4459-A2F1-937509C29401Q40014468-933EDCAA-0814-4032-9064-3C5C3FEB7EF6Q41548629-CDE525C0-A5E9-422E-AF5E-2775732AC476Q41698329-48C1C926-E0F1-40DB-80F7-7777EC233983Q42154119-74EA8EBD-AA34-48BD-90CE-290B0FBDA6F8Q42911830-2E3C7B96-50B3-4DC0-B5E5-6275A6A18C91Q43999592-6374C267-34E0-42A6-BD3A-BCC75020F6CA
P2860
The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas
description
im November 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2006
@uk
name
The Effects of SOM230 on Cell ...... orticotroph Pituitary Adenomas
@en
The Effects of SOM230 on Cell ...... orticotroph Pituitary Adenomas
@nl
type
label
The Effects of SOM230 on Cell ...... orticotroph Pituitary Adenomas
@en
The Effects of SOM230 on Cell ...... orticotroph Pituitary Adenomas
@nl
prefLabel
The Effects of SOM230 on Cell ...... orticotroph Pituitary Adenomas
@en
The Effects of SOM230 on Cell ...... orticotroph Pituitary Adenomas
@nl
P2093
P356
P1476
The Effects of SOM230 on Cell ...... orticotroph Pituitary Adenomas
@en
P2093
Brooke Swearingen
Dalia L. Batista
E. Tessa Hedley-Whyte
Peter J. Ansell
Roger Gejman
Sarah A. Johnson
Yunli Zhou
P304
P356
10.1210/JC.2006-1245
P407
P577
2006-11-01T00:00:00Z